Brinker Capital Investments LLC Sells 2,864 Shares of Accolade, Inc. (NASDAQ:ACCD)

Brinker Capital Investments LLC lessened its holdings in Accolade, Inc. (NASDAQ:ACCDGet Rating) by 3.3% during the third quarter, HoldingsChannel.com reports. The firm owned 83,551 shares of the company’s stock after selling 2,864 shares during the period. Brinker Capital Investments LLC’s holdings in Accolade were worth $954,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ACCD. MetLife Investment Management LLC lifted its position in shares of Accolade by 58.5% in the first quarter. MetLife Investment Management LLC now owns 28,794 shares of the company’s stock worth $506,000 after purchasing an additional 10,627 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Accolade in the first quarter worth $942,000. Rhumbline Advisers lifted its position in shares of Accolade by 6.7% in the first quarter. Rhumbline Advisers now owns 52,869 shares of the company’s stock worth $928,000 after purchasing an additional 3,312 shares in the last quarter. BlackRock Inc. lifted its position in shares of Accolade by 6.9% in the first quarter. BlackRock Inc. now owns 3,730,360 shares of the company’s stock worth $65,503,000 after purchasing an additional 241,048 shares in the last quarter. Finally, Bridgewater Associates LP lifted its position in shares of Accolade by 31.5% in the first quarter. Bridgewater Associates LP now owns 79,586 shares of the company’s stock worth $1,398,000 after purchasing an additional 19,074 shares in the last quarter. Institutional investors own 79.01% of the company’s stock.

Accolade Trading Up 3.0 %

ACCD stock opened at $9.17 on Monday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.14 and a current ratio of 3.14. The company’s 50-day simple moving average is $8.49 and its 200 day simple moving average is $10.05. Accolade, Inc. has a 52 week low of $4.61 and a 52 week high of $22.92. The company has a market capitalization of $667.46 million, a PE ratio of -1.38 and a beta of 1.36.

Accolade (NASDAQ:ACCDGet Rating) last released its quarterly earnings results on Monday, January 9th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Accolade had a negative net margin of 129.59% and a negative return on equity of 28.47%. The business had revenue of $90.95 million during the quarter, compared to analyst estimates of $87.53 million. During the same quarter last year, the company posted $0.31 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Accolade, Inc. will post -6.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ACCD has been the topic of several analyst reports. The Goldman Sachs Group upped their price target on shares of Accolade from $14.50 to $16.00 and gave the stock a “buy” rating in a research report on Friday, October 7th. SVB Leerink upped their price target on shares of Accolade from $8.00 to $13.00 and gave the stock a “market perform” rating in a research report on Friday, October 7th. Credit Suisse Group upped their price target on shares of Accolade from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Friday, October 7th. Canaccord Genuity Group upped their price target on shares of Accolade from $12.00 to $15.00 in a research report on Monday, October 3rd. Finally, DA Davidson dropped their price target on shares of Accolade from $16.00 to $14.00 in a research report on Tuesday, January 10th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.14.

Accolade Profile

(Get Rating)

Accolade, Inc, together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.

Recommended Stories

Want to see what other hedge funds are holding ACCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accolade, Inc. (NASDAQ:ACCDGet Rating).

Institutional Ownership by Quarter for Accolade (NASDAQ:ACCD)

Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.